Background/Aims: Increasing evidence showed that miR-1-3p plays a major role in malignant tumor progression. However, the specific biological function of miR-1-3p in bladder cancer is yet unknown. Methods: The expression levels of miR-1-3p in bladder cancer tissues and cell lines were examined by qRT-PCR. Bisulfite sequencing PCR was used for DNA methylation analysis. The target of miR-1-3p was validated by a dual luciferase reporter assay, and the effects of miR-1-3p on phenotypic changes in bladder cancer cells were investigated in vitro and in vivo. Results: The expression of miR-1-3p in bladder cancer cells was downregulated as compared to normal SV-HUC-1 cells. Also, the expression of miR-1-3p was significantly lower in bladder cancer tissues than the corresponding non-cancerous tissues. The methylation status of CpG islands was involved in the regulation of miR-1-3p expression. miR-1-3p inhibited the bladder cancer cell proliferation, migration, and invasion by directly targeting the 3'-UTR of glutaminase. It also exerted an anti-tumor effect by negatively regulating the glutaminase in a xenograft mouse model. Furthermore, GLS depletion resulted in the prolonged expression of γH2AX. Conclusion: Taken together, these results demonstrated that miR-1-3p acts as a tumor suppressor via regulation of glutaminase expression in bladder cancer progression, and miR-1-3p might represent a novel therapeutic target for the treatment of bladder cancer.
miR-1-3p Contributes to Cell Proliferation and Invasion by Targeting Glutaminase in Bladder Cancer Cells
and paired adjacent non-tumor bladder urothelial tissues were obtained from patients undergoing a surgical procedure at the Shanghai Tenth People's Hospital of Tongji University, School of Medicine (Shanghai, China) and immediately frozen in liquid nitrogen. All patients provided written consent, and the Ethics Committee from Tongji University approved the study.
Immunohistochemistry (IHC) staining
IHC was performed to detect the expression of GLS and Ki-67 in bladder cancer tumor tissues and xenograft tumor tissues. The tissue samples were fixed in 4% paraformaldehyde and processed for standard (4 μm) paraffin sectioning. Briefly, the paraffin tissue sections were dewaxed and rehydrated. Antigen retrieval was performed by heating the slides in sodium citrate buffer (10 mM, pH 6.0). After blocking with 1% goat serum, the sections were incubated with anti-Ki-67 (Cell Signaling Technology, Danvers, CA, USA), or anti-GLS (ab156876, Abcam, Cambridge, MA, USA). Subsequently, the slides were incubated with an HRP-linked secondary antibody (Cell Signaling Technology) for 1 h at room temperature, followed by color development using DAB (ZSGB-bio, Beijing, China). The strength of the positive signal was semi-quantified by considering both the intensity and proportion of positive cells.
Immunofluorescence analysis
T24 and UM-UC-3 cells were seeded and cultured in a 24-well plate inlaid with glass coverslips. After treatment, cells were fixed with 4% formaldehyde, blocked with 1% BSA followed by staining with antibodies against γH2AX (ab156876, Abcam). After being rinsed 3 times with PBS, the coverslips were then incubated with FITC-conjugated secondary antibodies for 1 h at room temperature. After counterstaining with 4, 6-diamidino-2-phenylindole (DAPI), the images were captured 63x magnification by using a confocal microscope (LSM710; Carl Zeiss, Jena, Germany).
Total RNA extraction and quantitative real-time PCR
Total RNA was extracted from frozen tissues and cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The concentration and purity of RNA were determined by ND-2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). For miR-1-3p detection, cDNA was synthesized using 1 μg of total RNA by One Step PrimeScript miRNA cDNA Synthesis Kit (Qiagen, Valencia, CA, USA). Quantitative real-time PCR (qRT-PCR) assay was performed using KAPA SYBR FAST qPCR Kit (Kapa Biosystems, Wilmington, MA, USA). The expression of miR-1-3p was normalized to that of U6.
For the detection of GLS mRNA level, cDNA was synthesized using PrimeScript RT Reagent Kit (TaKaRa, Shiga, Japan) according to the manufacturer's instructions. qRT-PCR was performed using KAPA SYBR FAST qPCR Kit (Kapa Biosystems). The mRNA expression level of GLS was normalized to that of β-actin. The relative expressions of miR-1-3p and GLS were calculated by the 2 -ΔΔCt method. All primers used are listed in Table 1 .
Overexpression or knockdown of miR-1-3p
miR-1-3p was overexpressed by transfecting the bladder cancer cell lines with a miRNA mimic, and knockdown was achieved by transfecting a miRNA inhibitor. Synthetic mim-miR-1-3p, anti-miR-1-3p, and the corresponding negative control scrambled RNAs (mimscramble and anti-scramble) were purchased from GenePharma (Shanghai, China). T24 and UM-UC-3 cells were seeded into 6-well plates in RPMI 1640 media supplemented with 10% FBS. On the following day, when 60-70% confluency was achieved, the cells were transfected with Lipofectamine 3000 (Invitrogen, 
Plasmid construction and siRNA interference assay
The GLS open reading frame (ORF) without the miR-1-3p-responsive 3'-UTR was cloned and inserted into the pcDNA3.1 vector by Sangon (Shanghai, China). An empty pcDNA3.1(+) served as the negative control. Two siRNA sequences targeting different sites of the human GLS cDNA (si-GLS) were designed and synthesized by Sangon. A scrambled siRNA that does not target the human GLS cDNA was synthesized and used as a negative control. The siRNA sequences are shown in Table 1 . Either the GLS overexpression plasmid or the GLS siRNAs were transfected into T24 and UM-UC-3 cells using Lipofectamine 3000 (Invitrogen). Total RNA and protein were isolated 24 h post-transfection. The GLS mRNA and protein expression levels were assessed by qRT-PCR and Western blotting, respectively. The siRNA sequence with the maximal interfering effect (si-GLS #1) was selected and used for all the subsequent experiments.
Construction of the miR-1-3p overexpression lentiviral vector
A lentiviral vector that overexpressed miR-1-3p was purchased from Lingke Biotechnology (Shanghai, China). T24 and UM-UC-3 cells were transduced with the lentiviruses and stable clones selected with 1 lg/ mL puromycin for 2 weeks, followed by harvesting the cells for subsequent experiments.
Cell proliferation assay
The Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) was used to measure the cell viability. Briefly, the transfected cells were seeded into 96-well plates at a density of 1000 cells/well. Then, 10 μL CCK-8 reagent was added to each well at indicated time points and incubated for 2 h at 37 °C. The absorbance at 450 nm was recorded using a microplate spectrophotometer (BioTek, Winooski, VT, USA).
Colony formation assay
Colony formation assays were performed to evaluate the cell proliferation. Briefly, cells were seeded in 6-well plates at approximately 1000 cells/well. After 14-d incubation, the cells were harvested and fixed with 75% ethanol, stained with 0.5% crystal violet, and visible colonies counted.
Wound healing assay
Wound healing assays were performed to detect the migration capacity of the cells. The transfected cells were seeded into 6-well plates and cultured until 80% confluency was achieved. A sterile 200 μL pipette tip was used to scratch the monolayer in each well. The wound closure was observed and images captured at 48 h after wounding and compared with the 0-h images.
Transwell assay
Transwell assays used transwell chambers (Corning; Tewksbury, MA, USA) coated with Matrigel (BD Biosciences; San Jose, CA, USA) on the upper surface. Briefly, 3×10
4 cells were seeded in the upper chambers in serum-free medium. The lower chambers were filled with RPMI 1640 medium containing 10% FBS. After 24 h incubation, the cells on the lower membrane were fixed with 75% ethanol for 20 min and stained with 0.5% crystal violet. Five visual fields were selected randomly, invaded cells counted, and imaged under a light microscope.
In vivo tumorigenicity assays
Four-week-old male BALB/c nude mice were purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences (Shanghai, China). The mice were randomly divided into two groups and subcutaneously injected with T24 cells (2 × 10 6 cells/mouse, n=5 mice/group) that were infected with either control lentivirus or a lentivirus that overexpressed miR-1-3p. Tumor growth curves were measured weekly with a caliper from week 1-5. The tumor volume was calculated by the following formula: tumor volume the weight of the tumor was measured. All animal studies were approved by the Institutional Animal Care and Use Committee of the Shanghai Tenth People's hospital.
5-aza-dc treatment and DNA methylation analysis
T24 and UM-UC-3 cells were first treated with 5 μM 5-aza-2′-deoxycytidine (5-aza-cdR) (Sigma, St Louis, MO, USA) for 4 days. Bisulfite-sequencing PCR (BSP) was used to assess the methylation levels of the CpG islands located near the TSS of miR-1-3p in T24 and UM-UC-3 cell lines. The primers (forward) 5'-GTTGGGTAGGTGAGGTGGTT -3' and (reverse) 5'-CCATTCTCTCCCTCCTTCTCTC -3' were used to amplify the DNA sequences of CpG islands via PCR. The samples were amplified by the following reaction: 98 °C for 4 min followed by 40 cycles of 94 °C for 45 s, 66 °C for 45 s, 72 °C for 1 min, and a final elongation at 72 °C for 8 min. PCR products were separated, extracted, and cloned using a pUC18-T-vector (Sangon). After bacterial amplification of the cloned PCR fragments by standard procedures, individual clones were sequenced (Sangon). Open and filled circles denote unmethylated and methylated CpG sites, respectively. Each row represents a single clone. The data were presented as percentages of the methylated/total CpGs in the plot.
Total protein extraction and Western blotting
The total protein of cells was extracted in RIPA buffer (Beyotime, Shanghai, China) supplemented with 1% PMSF and 1% protease inhibitor cocktail (Thermo Scientific 78440). The reaction was incubated on ice for 30 min and centrifuged for 10 min (12, 000 ×g, 4 °C). The supernatant was collected, and the protein concentration estimated using a Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). The GLS protein levels were analyzed by Western blotting using a monoclonal anti-human GLS antibody (ab156876, Abcam, Cambridge, MA, USA). The protein levels were normalized by stripping and probing the same blots with a β-actin antibody (Santa Cruz, Santa Cruz, CA, USA). The protein band was visualized using the Odyssey scanner (LI-COR Biosciences, Lincoln, NE, USA).
Dual luciferase reporter assay
To confirm the presence of miR-1-3p binding sites in the GLS 3'-UTR, GLS-wild-type 3'-UTR (GLSwt) and GLS-mutant 3'-UTR (GLS-mut) Luciferase reporter vectors were constructed. For luciferase assay, 293T cells were plated into 24-well plates and transfected with 100 ng luciferase reporter vectors and 100 nM of mim-miR-1-3p or mim-scramble. All plasmid vectors were purchased from Promega (Madison, WI, USA). The luciferase activity was measured using a luciferase reporter assay system (Promega) after 48 h incubation, according to the manufacturer's instructions.
Statistical analysis
Data were analyzed using SPSS 21.0 software (Chicago, IL, USA). Results are presented as mean ± standard deviation (SD) from at least three individual experiments for each group, the Student's t-test was performed to compare the difference of the two groups. P-value < 0.05 was considered statistically significant.
Results

miR-1-3p expression is decreased in bladder cancer tissues and cell lines
In order to verify the expression pattern of miR-1-3p in bladder cancer, we performed qRT-PCR on samples from 48 cases of bladder cancer tissues paired with adjacent nontumor bladder urothelial tissues, and in various bladder cancer cell lines in comparison with the SV-HUC-1 cells (a normal transitional epithelial cell line). The results indicated that the expression levels of miR-1-3p in cancer tissues were dramatically downregulated as compared to the adjacent non-tumor bladder urothelial tissues (Fig. 1A) . Similarly, the expression of miR-1-3p in four different cancer cell lines (EJ, J82, T24, and UM-UC-3) were also markedly low in contrast with SV-HUC-1 cells (Fig. 1B) . Collectively, these results verified the low expression pattern of miR-1-3p in bladder cancer and implied that miR-1-3p is a putative suppressor of bladder tumorigenesis.
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Methylation status of CpG islands is involved in the regulation of miR-1-3p expression
To delineate the mechanism underlying the downregulation of miR-1-3p in bladder cancer, we identified an explicit CpG island in the promoter region of miR-1-3p using the methylation software analysis: MethPrimer (http://www.urogene.org/methprimer/) (Fig.  1C) . Next, the T24 and UM-UC-3 cells were treated with 5-aza-2′-deoxycytidine (5-aza-cdR), a demethylating agent, to deduce the association between the methylation status of CpG islands and miR-1-3p expression. The results showed that the expression of miR-1-3p was substantially elevated in both cancer cell lines treated with 5-aza-cdR (Fig. 1D) . Finally, bisulfate sequencing analysis demonstrated that the DNA methylation levels were extremely high, 85% and 95%, in the two cancer cell lines, T24 and UM-UC-3, respectively (Fig. 1E, 1F ).
In conclusion, the above data indicated that the high methylation status of CpG islands might result in the inhibition of expression of miR-1-3p in bladder cancer.
miR-1-3p directly targets the 3'-UTR of GLS and inhibited its expression
To investigate the potential target of miR-1-3p, we combined the results from prediction databases (TargetScan, miRDB, and ComiR) and identified GLS as a putative target (Fig. 2A) . The efficient overexpression and knockdown of miR-1-3p in T24 and UM-UC-3 cells was 
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carrying a mutated miR-1-3p binding site was also constructed. Dual luciferase assays showed that while miR-1-3p suppressed the luciferase activity of the reporter containing the wild-type 3'-UTR of GLS in 293T cells, the effect was obviously abrogated with the mutated reporter (Fig. 2G) . Additionally, qRT-PCR (Fig. 2H ) and Western blot (Fig. 2I ) assays suggested a high expression of GLS in bladder cancer cell lines as compared to SV-HUC-1 cells. We also discovered that GLS was widely overexpressed in bladder cancer (Fig. 2J) .
miR-1-3p suppresses bladder cancer cell proliferation, migration, and invasion in vitro
The effects of miR-1-3p on bladder cancer cell proliferation were determined by CCK-8 and colony formation assays. Compared to the group transfected with the mim-scramble, T24 and UM-UC-3 cells transfected with mim-miR-1-3p exhibited a substantially reduced proliferation ability (Fig. 3A-E ). An opposite effect was observed in bladder cancer cells transfected with anti-miR-1-3p (Fig. 3A-E) . Next, we investigated whether miR-1-3p affected the bladder cancer cell migration and invasion. Wound healing assays showed that T24 and UM-UC-3 cells with increased miR-1-3p levels had slower recovery rates than the control cells; however, decreased miR-1-3p levels in bladder cancer cells led to faster wound closure than those of control cells (Fig. 3F-G) . Transwell assays showed a similar phenomenon, Transwell assays were used to assess the invasion ability of bladder cancer cells transfected with siGLS or negative control. *P<0.05, **P<0.01, ***P<0.001.
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in which, the miR-1-3p overexpression inhibited invasion, and decreased miR-1-3p levels accelerated the invasion of T24 and UM-UC-3 cells (Fig. 3H-I ). Taken together, these results suggested that miR-1-3p attenuated the proliferation, migration, and invasion of bladder cancer cells in vitro.
GLS is involved in the miR-1-3p-mediated regulation of bladder cancer cell growth, migration, and invasion
To examine whether miR-1-3p elicits the inhibitory effects on bladder cancer cells through GLS, we transfected T24 and UM-UC-3 cells with si-GLS, a small interfering RNA against GLS, to specifically knockdown the expression of GLS. The transfection of si-GLS remarkably suppressed the proliferation and colony formation ability in bladder cancer cells (Fig. 4A-D) , as well as downregulated the mRNA and protein levels of GLS simultaneously (Fig. 4E) , which was consistent with the effects of miR-1-3p on bladder cancer cells. Similarly, the bladder cancer cells with lower GLS expression levels showed suppressed cell migration and invasion capacities (Fig. 4F-G) . To better understand the reliance of miR-1-3p on GLS in modulating the biological behavior of bladder cancer cells, we overexpressed GLS and miR-1-3p and examined the cell proliferation, migration, and invasion abilities. Interestingly, the co-overexpression of GLS and miR-1-3p attenuated the tumor inhibitory role of miR-1-3p (Fig. 5A) , as shown by increased proliferation (Fig. 5B-E) , migration ( Fig. 5F-G) , and invasion ( Fig. 5H-I ) in both T24 and UM-UC-3 cells. Collectively, these data implied that miR-1-3p putatively suppressed proliferation and invasion of bladder cancer cells via GLS regulation.
miR-1-3p inhibits bladder cancer proliferation and tumorigenesis in vivo
Bladder cancer xenograft mouse models were used to explore the function of miR-1-3p in vivo. Consistent with the in vitro findings, the T24 cells overexpressing miR-1-3p had slower tumor growth rates and lower tumor volumes and tumor weights than the control group (Fig. 6A-C) . In addition, the tumors formed due to miR-1-3p overexpression carried fewer Ki-67 + cells and exhibiited lower GLS expression levels than those in the control group (Fig. 6D) . Taken together, the current data suggested a critical role for miR-1-3p in suppressing bladder cancer growth in vivo.
Knockdown of GLS specifically triggers DNA damage accumulation
To determine the impact of GLS on genomic integrity, we evaluated whether GLS depletion leads to accumulation of DNA damage. T24 and UM-UC-3 cells were transfected with si-GLS for 24 hours followed by immunofluorescence for γH2AX, an established biomarker for DNA damage. We found that knockdown of GLS led to a significant induction of γH2AX in both T24 and UM-UC-3 cells (Fig. 7A) . Consistently, western blot analysis revealed that knockdown of GLS induced γH2AX signal (Fig. 7B) . 
Discussion
Increasing evidence suggested that aberrant expression of miRNAs may contribute to tumorigenesis [26] . Moreover, strategies to identify the differentially expressed miRNAs and miRNA-targeted cancer pathways are under development as a new direction in cancer research. Abnormally expressed miRNAs have been demonstrated in several human cancers, including bladder cancer [11, 12, 27, 28] , although their function and mechanisms T24 and UM-UC-3 cells were transfected with si-GLS for 24 hours, and subjected to Western blot analysis using antibodies against γH2AX. in tumorigenesis are yet to be elucidated. In the present study, we revealed that the basic expression levels of miR-1-3p in bladder cancer tissues and cell lines were significantly downregulated as compared to the paired adjacent non-tumor bladder urothelial tissues and the non-tumor urothelial cell line, respectively, which was consistent with the previous study [18] . In addition, our findings indicated that miR-1-3p functions as tumor suppressors in bladder cancer for its effects on the inhibition of proliferation, migration and invasion. Similarly, Leone et al. found that miR-1-3p acted as a tumor-suppressed miRNA [16, 17] .
Interestingly, the epigenetic regulators, such as DNA methylation, can result in dysregulation of miRNA expression [29] . Herein, we reported that the expression levels of miR-1-3p sharply elevated in both cancer cell lines treated with 5-aza-cdR. Furthermore, we performed bisulfate analysis to explore that down-regulated miR-1-3p was mediated by DNA methylation. The DNA methylation levels were extremely high in the two cancer cell lines (T24 and UM-UC-3): 85% and 95%, respectively. Thus, our finding indicated that the methylation status of CpG islands was involved in the epigenetic regulation of miR-1-3p expression in bladder cancer.
Previous studies have shown that miR-1 plays a role as a tumor suppressor gene in prostate [13] , liver [14] , and lung [15] . In thyroid cancer, miR-1 is significantly downregulated and displays the anti-tumor effect via targeting CCND2, CXCR4, and SDF-1alpha [16] . miR-1 can inhibit the malignant transformation of bladder cancer cells by targeted regulation of TAGLN2 [17] . Shang et al. demonstrated that miR-1-3p inhibited bladder cancer cells with respect to proliferation, invasion and migration by up-regulating the expression of SFRP1 [18] . Accumulating evidence suggested that miRNAs have a unique ability to regulate multiple protein-coding genes via direct interaction with 3'-UTR of the target mRNAs. In order to explore the potential target genes of miR-1-3p, we combined the results from several different prediction databases and identified GLS as a candidate target gene of miR-1-3p. Furthermore, miR-1-3p inhibited both the protein and mRNA expressions of GLS. The luciferase reporter assay confirmed that miR-1-3p directly targeted the 3'-UTR of GLS. Additionally, GLS was upregulated in bladder cancer tissues and cell lines. The metabolic pathways have been recognized an essential hallmark of cancer [30] . In addition to elevated glycolysis, increased glutaminolysis is a characteristic of the tumor metabolic pathways. GLS is a critical enzyme for converting glutamine to glutamate in glutaminolysis [31] . It serves as an oncogene that promotes cancer progression and upregulation in various tumors [20, 32] . Based on these results, we hypothesized that miR-1-3p-mediated GLS inhibition might be a promising therapeutic option for bladder cancer.
To validate whether miR-1-3p plays a tumor-suppressive role by inhibiting GLS expression, we conducted gain-of-function and loss-of-function studies in bladder cancer cell lines. miR-1-3p overexpression inhibited the proliferation, migration, and invasion in bladder cancer cells, while the knockdown yielded opposite effects in vitro. Furthermore, GLS siRNA knockdown resulted in the inhibition of bladder cancer cell proliferation, migration, and invasion abilities, which was similar to the effects of miR-1-3p overexpression. However, overexpressing GLS abolished the inhibitory effects of miR-1-3p on bladder cancer cell proliferation, migration, and invasion. Furthermore, GLS depletion resulted in the prolonged expression of γH2AX, an established biomarker for DNA damage. Taken together, this evidence suggested that miR-1-3p may exert its tumor-suppressive effects via down-regulation of GLS in bladder cancer cells. As the weakness of our study, we didn't comprehensively reveal the mechanism by which GLS plays its roles in bladder cancer. Thus, further study is needed to fully understand the importance of GLS in the pathogenesis and development of bladder cancer. In addition, further validations are needed to confirm the great value of miR-1-3p in bladder cancer theranostics.
In summary, the current study demonstrated that miR-1-3p might function as a tumor suppressor through repression of oncogenic GLS in bladder cancer. miR-1-3p transfection and GLS knockdown inhibited the cell growth, migration, and invasion of bladder cancer cells. Thus, it is hypothesized that anticancer drugs containing miR-1-3p may be used as novel therapeutic modality characterized by the down-regulation of miR-1-3p. 
Conclusion
The current results showed that miR-1-3p expression was downregulated in bladder cancer tissues and cell lines. In addition, the in vivo and in vitro experiments revealed a critical role of miR-1-3p as a tumor suppressor in bladder cancer carcinogenesis. The molecular mechanisms underlying the aberrant miR-1-3p expression that contributes to bladder cancer progression were explored, and GLS identified as a direct target of miR-1-3p. Our study provides further insights into the pathogenesis of bladder cancer and mechanistic basis for improvements of therapeutic approaches.
